Image
A Breath of Fresh Air in Pediatric Asthma Shared Decision-making in the Era of Biologics

Mario Castro, MD, MPH; Wanda Phipatanakul, MD, MS

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical and Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas Medical Center
Kansas City, Kansas

Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

Statement of Need/Program Overview

Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.1 An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients. During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed April 14, 2021.
  2. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
  3. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
  4. Moorman JE, et al. Vital Health Stat 3. 2012(35):1-58.
  5. Sullivan SD, et al. Allergy. 2007;62(2):126-133.
  6. Strine TW, et al. Chest. 2004;126(6):1849-1854.
  7. Müllerová H, et al. J Asthma. 2020;1-12.
  8. American Lung Association. www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/asthma-children-facts-sheet#:~:text=In%202016%2C%203%2C651%20deaths%20were,adults%20over%2085%20years%20old. Accessed April 14, 2021.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
  • Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
  • Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
  • Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Physician Accrediation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Term of Offering

This activity was released on August 3, 2021 and is valid for one year. Requests for credit must be made no later than August 3, 2022.

System Requirements

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mario Castro, MD, MPH: Consultant: Genentech, Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceuticals USA, Inc.; Contracted Research: AstraZeneca, GlaxoSmithKline plc, Novartis International AG, Pulmatrix, Inc., Sanofi S.A., Shionogi Inc.; Honoraria: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.; Speakers Bureau: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.

Wanda Phipatanakul, MD, MS: Consultant: Genentech, Inc., GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.00

credit type CME/CE

release 08/03/2021

expiration 08/03/2022

type Webcast